This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 07-Jun-2022 and was forwarded to Moderna on 07-Jun-2022. This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (No adverse events other than testing positive for Covid-19) and INTERCHANGE OF VACCINE PRODUCTS (interchange of vaccine products) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Previously administered products included for Drug use for unknown indication: PFIZER BIONTECH COVID-19 VACCINE (Batch number- Unknown and Injection site- Left arm) on 13-Feb-2021. Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE. Concurrent medical conditions included HIV disease, High cholesterol, Grass allergy (Grass allergy), Allergy to plants (Trees allergy), Allergic to cats (cats allergy) and Allergic to dogs (Dogs allergy). Concomitant products included VALACYCLOVIR [VALACICLOVIR], ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE (TRIUMEQ), BIOCON [BIOTIN; CHLORPHENAMINE MALEATE; DIISOPROPYLAMINE DICHLOROACETATE; GLUCONATE SODIUM; NICOTINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN] from an unknown date to 19-May-2022 and FLUTICASONE PROPIONATE from an unknown date to 19-May-2022 for an unknown indication. On 13-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Oct-2021, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (No adverse events other than testing positive for Covid-19) and INTERCHANGE OF VACCINE PRODUCTS (interchange of vaccine products). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 18-May-2022 to 23-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (No adverse events other than testing positive for Covid-19) and INTERCHANGE OF VACCINE PRODUCTS (interchange of vaccine products) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Positive. It was also reported that patient took other medications/products within 2 weeks of starting the COVID-19 treatment and previously received a COVID-19 vaccine. Company comment: This spontaneous case reported by a patient, concerns a 50  year  old male patient with no relevant medical history, who experienced the unexpected nonserious AESI of COVID-19 infection, on an unknown date after receiving a dose of mRNA-1273 vaccine, considered as third dose of his COVID19 immunization schedule; the patient previously received a dose of Biontech COVID19 (interchange of vaccine products was considered) and a dose of mRNA1273 COVID19 vaccine. It was reported that the patient tested positive for COVID-19 and was treated with Nirmatrelvir, Ritonavir (Paxlovid) for five days. No further information was provided for medical reviewing. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. This case was linked to MOD-2022-584920 (Patient Link). Sender's Comments: This spontaneous case reported by a patient, concerns a 50yearold male patient with no relevant medical history, who experienced the unexpected nonserious AESI of COVID-19 infection, on an unknown date after receiving a dose of mRNA-1273 vaccine, considered as third dose of his COVID19 immunization schedule; the patient previously received a dose of Biontech COVID19 (interchange of vaccine products was considered) and a dose of mRNA1273 COVID19 vaccine. It was reported that the patient tested positive for COVID-19 and was treated with Nirmatrelvir, Ritonavir (Paxlovid) for five days. No further information was provided for medical reviewing. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.